返回 A A A Font Size Receive E-mail Alerts Press Releases

MicroPort® Endovascular Listed as "2017 Shanghai Patent Affairs Pilot Enterprise"

[2017-09-12] 

Shanghai, China - MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular") was recently listed as "2017 Shanghai Patent Affairs Pilot Enterprise" by Shanghai Intellectual Property Administration and will receive fund from Shanghai government and Pudong district government. Shanghai Intellectual Property Administration started to accept applications of patent demonstration/pilot enterprises since February and selected 95 companies as "2017 Shanghai Patent Affairs Pilot Enterprises" after expert review, group discussion, and authority approval.
 
Since its establishment, Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") has built a complete intellectual property management system based on its operation strategy, to manage intellectual property globally, control and prevent risks in infringement of intellectual property rights, as well as to realize strategic intellectual property application and management. With the same strategic goal as MicroPort®, MicroPort® Endovascular continues to carry out technology innovation and increase the awareness of its brand, and meanwhile, under the guidance of its parent company, it successfully established its own intellectual property management system which was granted China’s qualification certificate. MicroPort® Endovascular has done an outstanding job in patent invention, implementation, protection and management. Up to date, it applied for 120 patents, in which, 84 are Chinese patents, 15 are PCT patents, and 21 are overseas patents, and 82.5% of the applied patents are invention patents. At the same time, it gained 53 authorized patents.
 
Aside from MicroPort® Endovascular, another subsidiary of MicroPort® - Shanghai MicroPort EP MedTech Co., Ltd. ("MicroPort® EP") – was also listed as "Shanghai Patent Affairs Pilot Enterprise" in 2015. In the future, MicroPort® and its subsidiaries will continue to enhance the intellectual property management systems and patent data platforms to promote the industrialization of patented technologies, improve the efficiency in patent invention, application, protection and management, so as to translate patents into economic and social benefits.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 15 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 2017 MicroPort Scientific Corporation

CONTACT:
Amanda Zhang
Corporate Culture & Public Relations Director
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600-6989
Email: spokesperson@microport.com

 

[Prev]:MicroPort® Hosted the Investigator Meeting for Firehawk® TARGET CTO Trial in Beijing
[Next]:MicroPort® Endovascular Attends 2017 Vascular Intervention of Peking University